NASDAQ:BJDX - Bluejay Diagnostics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 784.96 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.13
▼ -0.03 (-2.59%)

This chart shows the closing price for BJDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bluejay Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BJDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BJDX

Analyst Price Target is $10.00
▲ +784.96% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bluejay Diagnostics in the last 3 months. The average price target is $10.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 784.96% upside from the last price of $1.13.

This chart shows the closing price for BJDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Bluejay Diagnostics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2022Dawson JamesInitiated CoverageBuy$10.00High
(Data available from 5/22/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Bluejay Diagnostics logo
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $1.13
Low: $1.10
High: $1.18

50 Day Range

MA: $1.12
Low: $0.94
High: $1.48

52 Week Range

Now: $1.13
Low: $0.82
High: $6.25

Volume

46,068 shs

Average Volume

195,494 shs

Market Capitalization

$22.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bluejay Diagnostics?

The following Wall Street sell-side analysts have issued stock ratings on Bluejay Diagnostics in the last twelve months: Dawson James, and Zacks Investment Research.
View the latest analyst ratings for BJDX.

What is the current price target for Bluejay Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Bluejay Diagnostics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 785.0%.
View the latest price targets for BJDX.

What is the current consensus analyst rating for Bluejay Diagnostics?

Bluejay Diagnostics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BJDX will outperform the market and that investors should add to their positions of Bluejay Diagnostics.
View the latest ratings for BJDX.

How do I contact Bluejay Diagnostics' investor relations team?

The company's listed phone number is 978-631-0152 and its investor relations email address is [email protected] The official website for Bluejay Diagnostics is www.bluejaydx.com. Learn More about contacing Bluejay Diagnostics investor relations.